Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety, Tolerability and Antiviral Activity of GS-9688 in Viremic Adult Subjects With Chronic Hepatitis B Who Are Not Currently on Treatment

Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety, Tolerability and Antiviral Activity of GS-9688 in Viremic Adult Subjects With Chronic Hepatitis B Who Are Not Currently on Treatment

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Jan 2019

At a glance

  • Drugs GS 9688 (Primary) ; Tenofovir alafenamide
  • Indications Hepatitis B
  • Focus Pharmacodynamics
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 24 Oct 2018 Planned End Date changed from 1 Apr 2020 to 1 Feb 2020.
    • 24 Oct 2018 Planned primary completion date changed from 1 Oct 2019 to 1 Sep 2019.
    • 31 Aug 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top